CJC-1295 (with DAC) is the long-acting form of the GHRH analog. The DAC (drug affinity complex) binds to plasma albumin, extending the half-life from 30 minutes to about a week. Used in research for sustained growth hormone elevation. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Albumin-binding GHRH analog
A long-acting GHRH analog with drug affinity complex (DAC) modification enabling weekly subcutaneous dosing through albumin binding.
Abstract
CJC-1295 with DAC (CJC-1295 long-acting; CAS 863288-34-0) is a modified GHRH 1-29 analog that incorporates a drug affinity complex (DAC) modification (a maleimidopropionyl-Lys side chain) which enables in vivo conjugation to circulating albumin through a covalent linkage with reduced cysteine 34. The albumin conjugation extends plasma half-life from minutes (for sermorelin) to approximately 6 to 8 days, enabling weekly subcutaneous dosing. The compound was developed by ConjuChem (Canada) and reached Phase 2 trials before being discontinued. The non-DAC version of CJC-1295 (without the albumin-binding modification) is the compound covered in our existing CJC-1295 nDAC monograph. The DAC version produces sustained mild GH and IGF-1 elevation rather than the pulsatile pattern of nDAC + GHRP combinations. Doses are 1 to 2 mg subcutaneously per week.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.